ExtraSuperTadarise is a combined preparation whose main ingredients include Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE).
What Is the Therapeutic Efficacy of ExtraSuperTadarise?
Therapeutic Efficacy for Erectile Dysfunction (ED)
Tadalafil, an ingredient in ExtraSuperTadarise, is a long-acting phosphodiesterase type 5 (PDE5) inhibitor that can significantly improve erectile function.
Clinical studies have shown that this medication can increase blood flow to the penis under sexual stimulation, helping to achieve and maintain sufficient erectile rigidity.
It has a relatively long duration of action, providing a more flexible time window for sexual activity.
Therapeutic Efficacy for Premature Ejaculation (PE)
Dapoxetine, another ingredient, is a selective serotonin reuptake inhibitor (SSRI) that can prolong the ejaculatory latency period.
Clinical observations have shown that this medication helps control ejaculation time, alleviates PE symptoms, and improves the quality of sexual life.
The two ingredients work synergistically to comprehensively improve male sexual dysfunction.
Comprehensive Therapeutic Efficacy
Through its dual effects, ExtraSuperTadarise not only addresses erectile issues but also extends intercourse duration, providing a comprehensive solution for patients with both ED and PE.
Its therapeutic efficacy has been verified in clinical practice, significantly improving patients’ sexual satisfaction and quality of life.
Applicable and Contraindicated Populations for ExtraSuperTadarise
Characteristics of Target Patients
Adult males aged 18 years and above.
Patients with concurrent erectile dysfunction (ED) and premature ejaculation (PE).
Patients who have an inadequate response to single-ingredient treatment and require combined therapy.
Contraindicated Populations
Patients using any form of nitrate drugs.
Patients with severe cardiovascular diseases or unstable angina pectoris.
Patients allergic to Tadalafil or Dapoxetine.
Patients with severe hepatic impairment.
Medication Monitoring for ExtraSuperTadarise
Pre-Treatment Assessment
Comprehensive cardiovascular system assessment.
Hepatic and renal function tests.
Detailed medication history review to avoid potential drug interactions.
Assessment of erectile function and ejaculatory control ability.
Key Monitoring Items During Treatment
Cardiovascular monitoring: Pay attention to changes in blood pressure and cardiac symptoms.
Hepatic function monitoring: Conduct regular tests of liver enzyme indicators.
Central nervous system monitoring: Watch for adverse reactions such as dizziness and drowsiness.
Visual monitoring: Be alert to abnormal color vision or changes in eyesight.
Mental status monitoring: Evaluate mood changes and depressive symptoms.
Special Monitoring Requirements
Close observation for adverse reactions is required after the first dose.
When used concomitantly with CYP3A4 inhibitors, monitor drug concentrations.
Regular efficacy assessment for long-term users.
Seek immediate medical attention if priapism (abnormal erection) lasts for more than 4 hours.
